Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IL6
REST API REST API
Homo sapiens
IL6 is differentially expressed in 257 experiments: 106 organism parts: lung, blood, ... (104 more);, 118 disease states: normal, lung adenocarcinoma, ... (116 more);, 83 cell types 328 cell lines 39 compound treatments and 65 other conditions.
Synonyms HSF, HGF, IFNB2, IL-6, BSF2
Orthologs IL6_CHICK (Gallus gallus)   IL6_BOVIN (Bos taurus)   Il6 (Mus musculus)   Il6 (Rattus norvegicus)   il6 (Xenopus laevis)   IL6_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of cell shape, defense response to virus, humoral immune response, positive regulation of JAK-STAT cascade, response to antibiotic, positive regulation of nitric oxide biosynthetic process, negative regulation of muscle organ development, protein binding, positive regulation of translation, response to wounding, cytokine-mediated signaling pathway, muscle cell homeostasis, regulation of cell proliferation, negative regulation of cell proliferation, extracellular space, negative regulation of protein kinase activity, acute-phase response, positive regulation of cell proliferation, positive regulation of gene expression, cell redox homeostasis, negative regulation of apoptosis, growth factor activity, extracellular region, receptor binding, cytokine activity, external side of plasma membrane, cell growth, defense response to protozoan, defense response to Gram-positive bacterium, positive regulation of transcription from RNA polymerase II promoter, response to peptidoglycan, neuron projection development, response to bacterium, response to caffeine, response to lipopolysaccharide, aging, positive regulation of DNA replication, defense response to Gram-negative bacterium, immune response, response to drug, response to cold, response to heat, positive regulation of transcription, DNA-dependent, response to mechanical stimulus, negative regulation of caspase activity, regulation of apoptosis, bone remodeling, positive regulation of immunoglobulin secretion, negative regulation of gluconeogenesis, response to cytokine stimulus, positive regulation of peptidyl-serine phosphorylation, response to nutrient levels, regulation of angiogenesis, neutrophil mediated immunity, negative regulation of collagen biosynthetic process, positive regulation of neuron differentiation, neuroprotection, positive regulation of peptidyl-tyrosine phosphorylation, positive regulation of ERK1 and ERK2 cascade, response to calcium ion, positive regulation of protein import into nucleus, translocation, regulation of vascular endothelial growth factor production, negative regulation of hormone secretion, branching involved in salivary gland morphogenesis, positive regulation of transmission of nerve impulse, T cell activation, regulation of circadian sleep/wake cycle, non-REM sleep, negative regulation of cytokine secretion, positive regulation of anti-apoptosis, positive regulation of epithelial cell proliferation, positive regulation of leukocyte chemotaxis, positive regulation of B cell activation, positive regulation of interleukin-6 production, negative regulation of lipid storage, negative regulation of fat cell differentiation, response to amino acid stimulus, interleukin-6 receptor complex, cellular response to hydrogen peroxide, response to insulin stimulus, neutrophil apoptosis, response to electrical stimulus, interleukin-6-mediated signaling pathway, epithelial cell proliferation involved in salivary gland morphogenesis, inflammatory response, positive regulation of osteoblast differentiation, monocyte chemotaxis, interleukin-6 receptor binding, endocrine pancreas development, positive regulation of T cell proliferation, positive regulation of smooth muscle cell proliferation, positive regulation of acute inflammatory response, positive regulation of MAPKKK cascade, positive regulation of chemokine production, positive regulation of protein kinase B signaling cascade, glucagon secretion, positive regulation of T-helper 2 cell differentiation, negative regulation of chemokine biosynthetic process, response to glucocorticoid stimulus, platelet activation, positive regulation of tyrosine phosphorylation of Stat3 protein, hepatic immune response, response to organic cyclic compound, positive regulation of sequence-specific DNA binding transcription factor activity, positive regulation of STAT protein import into nucleus
InterPro Term IL6_MGF_GCSF, Interleukin_6
UniProt Accession P05231, C9J5B0, B5MC21, B5MC14, B5MCZ3, B4DNV3, B4DNQ5, Q75MH2
Gene-Disease Assocation RHEUMATOID ARTHRITIS, SYSTEMIC JUVENILE, OSTEOPOROSIS, ARTERIOVENOUS MALFORMATIONS OF THE BRAIN, KAPOSI SARCOMA, INFLAMMATORY BOWEL DISEASE 1; IBD1, DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM
Search EB-eye ENSG00000136244
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-2549, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-2450, E-GEOD-4717, ... (33 experiments)

Factor Value U/D Experiments
BT474
2
E-MTAB-37, E-MTAB-62
primary culture
2
E-GEOD-2450, E-GEOD-1657
NCIH23
1
E-MTAB-37
BM1604
1
E-MTAB-37
GA10
1
E-MTAB-37
GM09581
1
E-TABM-321
322 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, ... (42 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-GEOD-3204
hematopoietic stem cell
2
E-MEXP-872, E-MEXP-1403
CD8 positive T-cell
1
E-GEOD-6338
CD34+ cell
1
E-MEXP-583
epidermal keratinocyte
1
E-GEOD-2822
mature monocyte derived dendritic cell
1
E-GEOD-4984
77 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-MEXP-1121, E-TABM-15, E-GEOD-16363, ... (50 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
glioblastoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-567
control
2
E-GEOD-20602, E-GEOD-16728
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
112 more value(s).


Compound treatment

studied in E-GEOD-1417, E-GEOD-697, E-GEOD-4748, E-TABM-868, E-GEOD-3140, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
5
E-TABM-868, E-GEOD-3140, E-MEXP-1958, E-GEOD-2706, E-GEOD-4748 ... (5 experiments)
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
nebivolol
1
E-GEOD-3356
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
MIG control
1
E-GEOD-15811
doxycycline
1
E-GEOD-2624
33 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
81
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-TABM-147 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-20115, E-TABM-868, E-MEXP-1648, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5809, E-GEOD-20540, E-GEOD-10315, E-GEOD-837, E-TABM-263, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-1290, E-GEOD-1432, E-GEOD-2466, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (9 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (8 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-TABM-147

Processing time: 0.388 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM